FDA Approves Piqray to Treat Breast Cancer

Home Blog FDA Approves Piqray to Treat Breast Cancer

The FDA recently approved the PI3K inhibitor Piqray for the treatment of postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following profession on or after an endocrine-based regimen. 

Piqray is the first PI3K inhibitor to show clinically meaninful benefit in treating patients with this type of breast cancer. Treating a patient's specific genetic mutation is becoming increasingly more common in cancer treatment. 

Read the full story from Cure.

0 comments

Back to Top